Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Prostatic Neoplasms × Adrenal Cortex Hormones × Clear all

Phase

Status

Unknown 1 Terminated 1 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Brain Neoplasms 3 Neoplasms 2 Radiation Pneumonitis 1 Radiation Injuries 1 Prostatic Neoplasms 1 Optic Neuritis 1 Neoplasm Metastasis 1 Myelitis, Transverse 1 Myelitis 1 Myasthenia Gravis 1 Lung Neoplasms 1 Lung Diseases, Interstitial 1 Glioma 1

Interventions

Magnetic Resonance Spectroscopy 49 Specimen Handling 38 enzalutamide 32 Radiosurgery 27 Androgen Antagonists 27 Radiotherapy 26 Abiraterone Acetate 23 Pluvicto 21 darolutamide 20 Prednisone 20 Docetaxel 19 apalutamide 17 Leuprolide 16 Standard of Care 15 Radiation 15 gallium 68 PSMA-11 13 Goserelin 13 Blood Specimen Collection 13 Biopsy 13 Triptorelin Pamoate 12 relugolix 11 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11 abiraterone 11 Surveys and Questionnaires 11 pembrolizumab 9 X-Rays 9 Photons 8 Methods 8 Interviews as Topic 8 Educational Status 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06925737 2026-03-13

MK-2400-001

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡